This study was originally published by Elsevier HS Journals on March 14, 2011. The objective of the study was to compare the efficacy and safety profile of a new proprietary oral vitamin B12 formulation (oral B12) with intramuscular (IM) vitamin B12 (IM B12) in restoring normal serum B12 concentrations in patients with low cobalamin levels
350pg/ml.
Vitamin B12 deficiency is routinely treated with parenteral dosing and less often with high-dose oral vitamin B12.
Oral vitamin B12 formulations have low bioavailability in patients with malabsorption and are considered less reliable than parenteral treatments.
Download to find out more.
More About This Company
Development Update
Novo Nordisk announced the European Commission (EC) has granted marketing authorisation for Rybelsus®, (oral semaglutide),...
Study: Pharmacokinetics of Oral Cyanocobalamin Formulated with SNAC
Originally published by Elsevier Journals on 24 May 2011, this white paper outlines an open-label,...
Emisphere Development Update
Novo Nordisk has announced the Federal Food and Drug Administration (FDA) approved Rybelsus, a semaglutide...